Update on toxicity and efficacy aspects of treatment with deferasirox and its implication on the morbidity and mortality of transfused iron loaded patients

Expert Opinion on Drug Safety

Volumn 7, Issue 6, 2008, Pages 645-646

  Kontoghiorghes, George J ^a  

^a Postgraduate Research Institute of Science Technology Environment and Medicine Limassol   (Cyprus)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM; COPPER; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; IRON; ZINC;

BIOACCUMULATION; BLOOD TRANSFUSION; CARDIOMYOPATHY; CAUSE OF DEATH; DRUG EFFICACY; DRUG FATALITY; DRUG MARKETING; DRUG SAFETY; DRUG USE; EDITORIAL; HEART; HUMAN; IRON CHELATION; IRON OVERLOAD; MORBIDITY; MORTALITY; PANCYTOPENIA;

BENZOIC ACIDS; BLOOD TRANSFUSION; DRUG THERAPY, COMBINATION; HEART; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; PYRIDONES; TRIAZOLES;

EID: 57049169920     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740330802137479     Document Type: Editorial

References (5)

1. Kontoghiorghes GJ: Deferasirox: uncertain future following renal failure fatalities, agranulocytosis and other toxicities. Expert Opin Drug Saf 2007;6:235-9
2. Anonymous: Deferasirox: for iron overload: only a third-line option. Prescrire Int 2007;16(91):196
3. Maggio A. Light and shadows in the iron chelation treatment of haematological diseases. Br J Haematol 2007;138:407-21
4. Kontoghiorghes GJ. Ethical issues and risk/benefit assessment on iron chelation therapy: advances with defefiprone/deferoxamine combination and concerns about the safety, efficacy and costs of deferasirox. Hemoglobin 2008;32:1-15
5. Anonymous. Treating the kidney to treat the heart. Product CMX001 (deferiprone). Available from: http://www.cormedix.com